Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

Carfilzomib, a selective proteasome inhibitor, was approved in 2012 for the treatment of relapsed and refractory multiple myeloma. Safety data for single-agent carfilzomib have been analyzed for 526 patients with advanced multiple myeloma who took part in one of 4 phase II studies (PX-171-003-A0, PX...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Main Authors: Siegel, David, Martin, Thomas, Nooka, Ajay, Harvey, R. Donald, Vij, Ravi, Niesvizky, Ruben, Badros, Ashraf Z., Jagannath, Sundar, McCulloch, Leanne, Rajangam, Kanya, Lonial, Sagar
Formáid: Artigo
Teanga:Inglês
Foilsithe: Ferrata Storti Foundation 2013
Ábhair:
Articles
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3815177/
https://ncbi.nlm.nih.gov/pubmed/23935022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2013.089334
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla